LP-184 is effective in patient-derived solid tumor models. LP-184 ex vivo potency in a 5-day cell proliferation assay compared with olaparib in a panel of HRD patient-derived tumor graft models representing multiple solid tumor types
No takes yet. Share an insight, caveat, or question.
Kulkarni et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: